Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Letters to the Editor
Open Access

Authors’ Reply

Daniel Batlle, Maria Jose Soler, Paul A. Welling, Sundararaman Swaminathan and on behalf of the COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group*
JASN August 2020, 31 (8) 1918-1919; DOI: https://doi.org/10.1681/ASN.2020060799
Daniel Batlle
1Nephrology Division, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Jose Soler
2Nephrology Division, Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul A. Welling
3Nephrology Division, Johns Hopkins University, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sundararaman Swaminathan
4Nephrology Division, University of Virginia, Charlottesville, Virginia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • covid-19
  • acute renal failure
  • ace2
  • soluble ACE2
  • AKI
  • ACE inhibitors
  • Angiotensin II receptor blockers

In our Perspective article, we aimed to discuss the emerging mechanisms that might be involved in the pathophysiology of coronavirus disease 2019 (COVID-19)–associated AKI and emphasized the need for more information. At the time of writing, data were largely limited to the two studies from China reporting data from autopsies. We refrained from speculating about therapies because we felt that it would be premature and speculative.

We are not aware that angiotensin-receptor blockers could compete with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for angiotensin-converting enzyme 2 (ACE2) and block the binding of the virus. In fact, these agents do not bind to ACE2 and therefore any connection would have to be indirect.1,2 Some studies have shown upregulation of ACE2 by angiotensin-receptor blockers.3 The significance of this finding remains unclear regarding infectivity by SARS-CoV-2 and the course of COVID-19 and its manifestations, including AKI.1,2 Concerning the potential use of renin-angiotensin system (RAS) blockers to protect the kidneys in patients with COVID-19, we see pros and cons as is the case in other forms of AKI.4 Angiotensin II is upregulated in AKI in general and this may be exacerbated in COVID-19–associated AKI if ACE2 is suppressed as has been hypothesized. In this regard, the use of RAS blockers could be beneficial but one needs to be mindful of their hypotensive action that may limit their use. A shorter variant of ACE2 that is filterable by the glomerular filtration barrier has been shown to prevent/attenuate AKI in the ischemia-reperfusion model in mice (M. Shirazi, Y, Wysocki, M. Ye, C. Haney, M. Zhao, Y.S. Kanwar, et al.: A novel ACE2 truncate for acute kidney injury, 2019).5 This could be a better approach, in our opinion, than the use of RAS blockade in the setting of AKI, but this is speculative owing to the lack of human studies. In addition, soluble ACE2 could bind SARS-CoV-2, acting as a decoy so that viral uptake by the membrane-bound full-length ACE2 would be greatly diminished, thereby potentially providing a much-needed therapy for COVID-19.6

Disclosures

D. Batlle is a coinventor of a patent Active Low Molecular Weight Variants of Angiotensin Converting Enzyme 2, and founder of Angiotensin Therapeutics Inc. All remaining authors have nothing to disclose.

Funding

D. Batlle was funded by National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK104785.

Acknowledgments

Dr. Maria Jose Soler reports personal fees from NovoNordisk, personal fees from Janssen, non-financial support from Boehringer, non-financial support from Eli Lilly, personal fees from AstraZeneca, personal fees and non-financial support from Esteve, personal fees from FMC, and personal fees from Mundipharma, outside the submitted work.

Footnotes

  • ↵* The COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group members are as follows: Matthew A. Spar ks,SwapnilHiremath,DanielBatlle, Andrew South, Paul Welling, J. Matt Luther, Jordana Cohen, James Brian Byrd, Louise M. Burrell, Laurie Tomlinson, Vivek Bhalla, María José Soler, and Sundar Swaminathan.

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related Letters to the Editor, “Possible Protective Effect of Renin-Angiotensin System Inhibitors in COVID-19 Induced Acute Kidney Injury,” on pages 1917–1918.

  • Copyright © 2020 by the American Society of Nephrology

References

  1. ↵
    1. Danser AHJ,
    2. Epstein M,
    3. Batlle D
    : Renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 75: 1382–1385, 2020
    OpenUrl
  2. ↵
    1. Sparks MA,
    2. South A,
    3. Welling P,
    4. Luther JM,
    5. Cohen J,
    6. Byrd JB, et al.
    : Sound science before quick judgement regarding RAS blockade in COVID-19. Clin J Am Soc Nephrol 15: 714–716, 2020 pmid:32220930
    OpenUrlFREE Full Text
  3. ↵
    1. Ferrario CM,
    2. Jessup J,
    3. Chappell MC,
    4. Averill DB,
    5. Brosnihan KB,
    6. Tallant EA, et al.
    : Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605–2610, 2005 pmid:15897343
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Coca SG,
    2. Garg AX,
    3. Swaminathan M,
    4. Garwood S,
    5. Hong K,
    6. Thiessen-Philbrook H, et al.
    ; TRIBE-AKI Consortium: Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and Acute Kidney Injury in patients undergoing cardiac surgery. Nephrol Dial Transplant 28: 2787–2799, 2013
    OpenUrlCrossRefPubMed
  5. ↵
    1. Wysocki J,
    2. Schulze A,
    3. Batlle D
    : Novel variants of angiotensin converting enzyme-2 of shorter molecular size to target the kidney renin angiotensin system. Biomolecules 9: 886, 2019 pmid:31861139
    OpenUrlCrossRefPubMed
  6. ↵
    1. Batlle D,
    2. Wysocki J,
    3. Satchell K
    : Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond) 134: 543–545, 2020 pmid:32167153
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 31 (8)
Journal of the American Society of Nephrology
Vol. 31, Issue 8
August 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Authors’ Reply
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Authors’ Reply
Daniel Batlle, Maria Jose Soler, Paul A. Welling, Sundararaman Swaminathan, on behalf of the COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group*
JASN Aug 2020, 31 (8) 1918-1919; DOI: 10.1681/ASN.2020060799

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Authors’ Reply
Daniel Batlle, Maria Jose Soler, Paul A. Welling, Sundararaman Swaminathan, on behalf of the COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group*
JASN Aug 2020, 31 (8) 1918-1919; DOI: 10.1681/ASN.2020060799
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Authors’ Reply: Anti-Hinge Antibodies Are Likely to Be of Minor Importance
  • Endopeptidase Therapy for Anti-Glomerular Basement Membrane Disease: Beware of Anti-Hinge Antibodies!
  • Response to “The Advancing American Kidney Health Initiative: The Challenge of Overcoming the Status Quo” and “The Advancing American Kidney Health Initiative: Do Not Let 80% Distract Us from the Fact that We Can Do Better”
Show more Letters to the Editor

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Possible Protective Effect of Renin-Angiotensin System Inhibitors in COVID-19 Induced Acute Kidney Injury
  • PubMed
  • Google Scholar

Keywords

  • COVID-19
  • acute renal failure
  • ace2
  • soluble ACE2
  • AKI
  • ACE inhibitors
  • Angiotensin II receptor blockers

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire